Adding ACE inhibitor doesn’t improve outcomes in stable angina and normal LVEF

Adding the angiotensin-converting enzyme (ACE) inhibitor trandolapril (Mavik) to standard medical treatment of patients with stable angina and normal left ventricular function did not reduce their risk of adverse cardiovascular outcomes. Although higher-risk patients and those with less well controlled risk factors may still benefit from this intervention, this study didn’t assess those groups. (LOE=1b)

Adding the angiotensin-converting enzyme (ACE) inhibitor trandolapril (Mavik) to standard medical treatment of patients with stable angina and normal left ventricular function did not reduce their risk of adverse cardiovascular outcomes. Although higher-risk patients and those with less well controlled risk factors may still benefit from this intervention, this study didn’t assess those groups. (LOE=1b)

Adding the angiotensin-converting enzyme (ACE) inhibitor trandolapril (Mavik) to standard medical treatment of patients with stable angina and normal left ventricular function did not reduce their risk of adverse cardiovascular outcomes. Although higher-risk patients and those with less well controlled risk factors may still benefit from this intervention, this study didn’t assess those groups. (LOE=1b)